Gepubliceerd in:
01-04-2013 | ICIN
Rate control in atrial fibrillation, insight into the RACE II study
Auteurs:
H. F. Groenveld, H. J. G. M. Crijns, J. G. P. Tijssen, M. Alings, H. L. Hillege, Y. S. Tuininga, M. P. Van den Berg, D. J. Van Veldhuisen, I. C. Van Gelder
Gepubliceerd in:
Netherlands Heart Journal
|
Uitgave 4/2013
Log in om toegang te krijgen
Excerpt
Currently, in Europe, more than 6 million patients have atrial fibrillation (AF) [
1]. It is expected that this number will double in the next 30–50 years [
1‐
3]. With AF, the risk of death, stroke and heart failure is increased [
4‐
6], and exercise capacity and quality of life are reduced [
7,
8]. Thus, AF is not a benign disease. Despite efforts to maintain sinus rhythm, AF is a progressive arrhythmia [
9‐
11] and many patients eventually develop permanent AF. Until recently, the treatment of this specific patient group was not evidence based. An evidence-based treatment strategy is indispensable considering the large patient population. …